People with Asthma Who Take Weight Loss Drug Semaglutide Have Fewer Attacks, Study Shows

The medication semaglutide, traditionally prescribed for weight loss and diabetes management, has been found to reduce asthma attacks in patients. This breakthrough was discovered through a study conducted on existing users of the drug, which is sold under brand names such as Ozempic or Wegovy.

Historically, asthma management has focused on bronchodilators and corticosteroids to alleviate symptoms. However, the study’s findings suggest that semaglutide may be a game-changer in respiratory care. The connection between semaglutide and reduced asthma attacks was strongest among those receiving higher doses of the medication, indicating a dose-response relationship.

Individuals with more pronounced asthma appeared to benefit most from semaglutide treatment. This could indicate that the medication is particularly effective for patients whose asthma is not well-controlled by traditional treatments or who experience frequent exacerbations. Experts caution against using semaglutide specifically for lung health outside current prescribing guidelines, but the study’s findings are undeniably encouraging.

Dr. Alexander Mathioudakis noted that this research highlights the need to consider metabolic health as part of respiratory care. This underscores the importance of a more holistic approach to treating chronic conditions like asthma. The implications for patients living with both diabetes or obesity and lung disease are significant, with potential benefits including improved quality of life, reduced healthcare costs, and a better prognosis.

The study raises pressing questions about the current state of lung health research funding in the UK. Dr. Samantha Walker’s call to action emphasizes that “funding for lung health research is on life support.” It is imperative that policymakers take notice and allocate more resources to investigating innovative treatments like semaglutide, which could potentially transform the lives of millions.

The European Respiratory Society Congress in Barcelona, where this study was presented, serves as a stark reminder of the need for continued investment in respiratory research. With lung conditions remaining the third biggest cause of death in the UK, it is unconscionable to let funding languish while lives hang in the balance.

As researchers await further studies to confirm these findings and explore semaglutide’s potential, one thing is clear: this breakthrough has the potential to change the treatment landscape for patients with asthma – and, by extension, those living with chronic conditions more broadly.